Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I-III Breast Cancer Patients

被引：3

作者：

Lin, Wea-Lung ^{[1
]}

Chen, Fong-Lin ^{[2
]}

Han, Chih-Ping ^{[1
,3
,4
]}

机构：

[1] Chung Shan Med Univ, Sch Med, Dept Pathol, Taichung, Taiwan

[2] Chung Shan Med Univ Hosp, Dept Pediat, Div Pediat Cardiol, Taichung, Taiwan

[3] Chung Shan Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan

[4] Chung Shan Med Univ Hosp, Clin Trial Ctr, Taichung, Taiwan

来源：

ANNALS OF SURGICAL ONCOLOGY | 2011年 / 18卷

关键词：

Antigenic Determinant; Disseminate Tumor Cell; Operable Breast Cancer; Remarkable Advantage; Hypaque;

D O I：

10.1245/s10434-010-1419-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S261 / S262

页数：2

共 10 条

[1] Anti-cytokeratin CAM5.2 (BD Biosciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients
Wea-Lung Lin
Fong-Lin Chen
Chih-Ping Han
Annals of Surgical Oncology, 2011, 18 : 261 - 262
[2] Anti-cytokeratin CAM5.2 (BD Sciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients
Savitri Krishnamurthy
Anthony Lucci
Annals of Surgical Oncology, 2011, 18 : 263 - 264
[3] Anti-cytokeratin CAM5.2 (BD Sciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I-III Breast Cancer Patients
Krishnamurthy, Savitri
Lucci, Anthony
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 : S263 - S264
[4] Anti-Cytokeratin CAM5.2 Reagent (Becton Dickinson Biosciences) Can Detect CK 8, Not CK8/18 Comment on "Sonographic Findings in a Patient with Neurofibromatosis Type 1 and a Gastrointestinal Stromal Tumor,"J Clin Ultrasound 2010 Jan 20 [Epub ahead of print]
Chen, Pin-Jie
Hsu, Jeng-Dong
Han, Chih-Ping
JOURNAL OF CLINICAL ULTRASOUND, 2010, 38 (07) : 384 - 384
[5] Anti-Cytokeratin CAM5.2 Reagent (Becton Dickinson Biosciences) Can Detect CK 8, Not CK8/18 Comment on "Sonographic Findings in a Patient with Neurofibromatosis Type 1 and a Gastrointestinal Stromal Tumor,"J Clin Ultrasound 2010 Jan 20 [Epub ahead of print] Reply
De Zordo, Tobias
JOURNAL OF CLINICAL ULTRASOUND, 2010, 38 (07) : 385 - 385
[6] Reply to “Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on ‘Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227–35’”
Bas B. Koolen
Jelle Wesseling
Annals of Surgical Oncology, 2014, 21 : 700 - 700
[7] Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on “Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. Annals of Surgical Oncology doi: 10.1245/s10434-013-2902-0 (2013)”
Wan-Ru Chao
Chih-Ping Han
Annals of Surgical Oncology, 2014, 21 : 699 - 699
[8] Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on "Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II-III Breast Cancer: Implications for Surgical Management of the Axilla. Annals of Surgical Oncology doi: 10.1245/s10434-013-2902-0 (2013)"
Chao, Wan-Ru
Han, Chih-Ping
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (02) : 699 - 699
[9] Reply to "Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on 'Early Assessment of Axillary Response with 18F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II-III Breast Cancer: Implications for Surgical Management of the Axilla. Ann Surg Oncol. 2013;20(7):2227-35'"
Koolen, Bas B.
Wesseling, Jelle
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (02) : 700 - 700
[10] Anti-Cytokeratin CAM5.2 (BD) does not act as a substitute of the CK8/18 monoclonal antibody. Comment on: 'Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and-2 in spinal chordoma'. Histopathology 2009; 54; 607-613
Naka, Takahiko
HISTOPATHOLOGY, 2010, 56 (06) : 810 - 811

← 1 →